Comparative anti-inflammatory potential of ingredients of Purandara Vati and Shwasakuthar Rasa: A preclinical evidence based portrayal

Abstract

Asthma is a multifaceted, long-term inflammatory disease linked to tissue remodelling of the airway structure and hyper-responsiveness of the airways. The goal is to get the best asthma control possible while using the least amount of medication. It has been reported that oral consumption of corticosteroids increases the chances of osteoporosis, bone fractures, cataracts, pneumonia, opportunistic lung infections, diabetes, and obesity in those with asthma. Inhaled corticosteroids have also been linked to an increased risk of cataract development, respiratory infections, and BMD loss in asthmatic patients. Aspirin and NSAIDs have enormous side effects, such as hyperacidity and gastrointestinal disturbances, so long-term use of these medications is not recommended. Therefore, medications with few adverse effects and strong anti-inflammatory and asthmatic effects are needed to treat inflammatory disease. Shwasakuthara rasa and Purandara Vati are two well-known formulations for management of asthma with quite similar ingredients and can be therapeutically implemented as anti-inflammatory formulation. This article delineates preclinical evidences for anti-inflammatory potential Shwaskuthara rasa and Purandara Vati.